Please assess the completion status of the following clinical trial:

Trial Title: Serum-derived Bovine Immunoglobulin Effect on Mucositis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Informed consent obtained and signed~2. Male or female at least 18 years of age~3. Diagnosed with head, neck, or lung cancer and scheduled to undergo combined chemo-radiation therapy~4. Diagnosed with head, neck, or lung cancer with disease stage within the criteria described in 4.0 Staging Criteria~5. Not experiencing diarrhea during the 5 days preceding enrollment, as defined by having less than two unformed bowel movements per day or loose (mushy) or watery stools in the 5 days preceding enrollment.~6. Not currently taking anti-diarrheal medications (prescription or over the counter).~7. Agrees and is able to take the investigational products or placebo starting from the day of enrollment (approximately 7-14 days prior to beginning chemo-radiation therapy) through 6-7 weeks of chemo-radiation therapy (for a total of 8-9 weeks).~Exclusion Criteria:~1. History of uncontrolled diarrhea during screening.~2. History of Irritable Bowel Syndrome with Diarrhea with a normal pattern of more than three bowel movements in a 24 hour period.~3. History of inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis.~4. History of active infectious diarrhea and receiving therapy within 10 days of the first dose of study drug or placebo.~5. Known allergy or intolerance to beef or soy or any ingredient used in the product~6. History of concurrent intensive chemotherapy within 10 days of the first scheduled dose of study drug or placebo.~7. Gastrointestinal surgery or bowel resection that could affect study product absorption (this does not include cholecystectomy or appendectomy).~8. Unable to comply with the protocol requirements.~9. Any condition that in the opinion of the Investigator might interfere with the study objective.~10. Women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nutritional therapy (Type: ACTIVE_COMPARATOR): Serum-derived bovine immunoglobulin/protein isolate (SBI) 10.0 grams once daily
- Placebo (Type: PLACEBO_COMPARATOR): Hydrolyzed gelatin 10.0 grams once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).